Twist Bioscience Corporation

TWST

Equity

ISIN US90184D1000 / Valor 44023909

NASDAQ (2024-09-18)

USD 47.02-1.36%

Twist Bioscience Corporation
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Twist Bioscience Corporation is a company that specializes in providing NGS Target Enrichment Panels, NGS Reagents and Kits, Synthetic RNA Controls, Synthetic Respiratory Controls, and Synthetic DNA Controls. The company has received ISO 13485:2016 certification for its quality management system and is also ISO 27001:2013 certified for information security management.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Twist Bioscience Corporation reported a significant increase in total revenue for the second quarter of fiscal 2024, reaching $75.3 million. This marks a notable growth compared to the $60.2 million reported for the same period in fiscal 2023.

Order Increase

In the second quarter of fiscal 2024, Twist Bioscience Corporation saw a substantial rise in total orders received, which amounted to $93.2 million. This represents a 45% increase from the $64.2 million in orders received during the second quarter of fiscal 2023.

Gross Margin Improvement

Twist Bioscience Corporation achieved a significant improvement in gross margin for the second quarter of fiscal 2024, which increased to 41%. This is a considerable enhancement from the 31% gross margin reported in the second quarter of fiscal 2023.

Net Loss Reduction

The net loss attributable to common stockholders for Twist Bioscience Corporation in the second quarter of fiscal 2024 was $45.5 million, or $0.79 per share. This is an improvement compared to the net loss of $59.2 million, or $1.04 per share, reported for the same period in fiscal 2023.

Updated Financial Guidance

Twist Bioscience Corporation has updated its financial guidance for fiscal 2024, projecting total revenue to be in the range of $300 million to $304 million. This is an increase from the previous guidance of $288 million to $293 million, indicating a year-over-year growth of 22% to 24%.

Summarized from source with an LLMView Source

Key figures

129%1Y

-61.4%3Y

57.7%5Y

Performance

75.3%1Y

81.5%3Y

81.3%5Y

Volatility